Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ$15.095
Market Cap
$2.07B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
312 of 924
Rank in Industry
179 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
ARWR Insider Trading Activity
ARWR Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $82,990 | 3 | 13 |
Sells | $10,368,351 | 21 | 87 |
Related Transactions
| Lu Hongbo | director | 3 | $82,990 | 0 | $0 | $82,990 |
| OLUKOTUN ADEOYE Y | director | 0 | $0 | 2 | $77,139 | $-77,139 |
| GIVEN DOUGLAS B | director | 0 | $0 | 2 | $121,556 | $-121,556 |
| Waddill William D. | director | 0 | $0 | 2 | $164,665 | $-164,665 |
| Oliver Tracie | Chief Commercial Officer | 0 | $0 | 1 | $237,480 | $-237,480 |
| Vakiener Victoria | director | 0 | $0 | 2 | $238,993 | $-238,993 |
| O'Brien Patrick | COO and General Counsel | 0 | $0 | 2 | $736,059 | $-736,059 |
| Hamilton James C | Chief Discovery/Trans Medicine | 0 | $0 | 2 | $817,004 | $-817,004 |
| Myszkowski Kenneth Allen | Chief Financial Officer | 0 | $0 | 2 | $893,095 | $-893,095 |
| Anzalone Christopher Richard | Chief Executive Officer | 0 | $0 | 6 | $7.08M | $-7.08M |
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in …
Insider Activity of Arrowhead Pharmaceuticals, Inc.
Over the last 12 months, insiders at Arrowhead Pharmaceuticals, Inc. have bought $82,990 and sold $10.37M worth of Arrowhead Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Arrowhead Pharmaceuticals, Inc. have bought $52,573 and sold $21.24M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lu Hongbo (director) — $82,990.
The last purchase of 1,000 shares for transaction amount of $27,500 was made by Lu Hongbo (director) on 2024‑03‑20.
List of Insider Buy and Sell Transactions, Arrowhead Pharmaceuticals, Inc.
| 2025-03-13 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 51,425 0.0374% | $15.07 | $774,975 | +1.92% | |
| 2025-03-04 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 133,333 0.104% | $17.02 | $2.27M | -9.53% | |
| 2025-03-03 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 166,667 0.1344% | $18.03 | $3.01M | -11.91% | |
| 2025-01-23 | Sale | OLUKOTUN ADEOYE Y | director | 959 0.0007% | $21.00 | $20,139 | -11.24% | |
| 2025-01-07 | Sale | O'Brien Patrick | COO and General Counsel | 8,000 0.0065% | $19.69 | $157,520 | -2.85% | |
| 2025-01-07 | Sale | Myszkowski Kenneth Allen | Chief Financial Officer | 18,000 0.0146% | $19.69 | $354,500 | -2.85% | |
| 2025-01-06 | Sale | O'Brien Patrick | COO and General Counsel | 29,184 0.0236% | $19.82 | $578,539 | -0.92% | |
| 2025-01-06 | Sale | Myszkowski Kenneth Allen | Chief Financial Officer | 27,167 0.022% | $19.83 | $538,595 | -0.92% | |
| 2025-01-06 | Sale | Hamilton James C | Chief Discovery/Trans Medicine | 32,729 0.0265% | $19.82 | $648,824 | -0.92% | |
| 2025-01-02 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 11,520 0.009% | $19.05 | $219,456 | -0.69% | |
| 2024-12-27 | Sale | OLUKOTUN ADEOYE Y | director | 2,850 0.0024% | $20.00 | $57,000 | +2.85% | |
| 2024-12-23 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 12,563 0.0099% | $19.59 | $246,109 | -1.19% | |
| 2024-12-18 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 26,712 0.0226% | $21.24 | $567,486 | -4.22% | |
| 2024-12-17 | Sale | GIVEN DOUGLAS B | director | 547 0.0004% | $22.04 | $12,056 | -12.37% | |
| 2024-12-17 | Sale | Waddill William D. | director | 3,747 0.003% | $22.04 | $82,584 | -12.37% | |
| 2024-12-16 | Sale | GIVEN DOUGLAS B | director | 5,000 0.004% | $21.90 | $109,500 | -12.70% | |
| 2024-12-16 | Sale | Waddill William D. | director | 3,748 0.003% | $21.90 | $82,081 | -12.70% | |
| 2024-12-16 | Sale | Vakiener Victoria | director | 8,994 0.0071% | $21.91 | $197,059 | -12.70% | |
| 2024-07-02 | Sale | Oliver Tracie | Chief Commercial Officer | 9,394 0.0073% | $25.28 | $237,480 | -19.19% | |
| 2024-05-02 | Sale | Vakiener Victoria | director | 1,799 0.0014% | $23.31 | $41,935 | -11.15% |
Total: 232
*Gray background shows transactions not older than one year
Insider Historical Profitability
24.46%
| Anzalone Christopher Richard | Chief Executive Officer | 4062377 2.9584% | $61.32M | 4 | 41 | <0.0001% |
| Myszkowski Kenneth Allen | Chief Financial Officer | 455433 0.3317% | $6.87M | 1 | 29 | <0.0001% |
| GIVEN DOUGLAS B | director | 124167 0.0904% | $1.87M | 1 | 21 | <0.0001% |
| Lu Hongbo | director | 33680 0.0245% | $508,399.60 | 3 | 0 | |
| KNOTT DAVID M | 10 percent owner | 166778 0.1215% | $2.52M | 1 | 3 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$66,492,695 | 135 | 27.65% | $2.05B | |
$1,376,668 | 53 | 18.46% | $2.31B | |
$11,583,737 | 45 | 49.75% | $1.76B | |
$224,267,561 | 40 | 26.78% | $2.17B | |
$148,770,544 | 34 | 80.63% | $1.74B |
ARWR Institutional Investors: Active Positions
| Increased Positions | 137 | +43.63% | 10M | +10.01% |
| Decreased Positions | 131 | -41.72% | 8M | -7.87% |
| New Positions | 45 | New | 2M | New |
| Sold Out Positions | 44 | Sold Out | 2M | Sold Out |
| Total Postitions | 320 | +1.91% | 101M | +2.14% |
ARWR Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $248,494.00 | 11.81% | 16.18M | +342,088 | +2.16% | 2024-12-31 |
| Vanguard Group Inc | $187,151.00 | 8.89% | 12.18M | -44,766 | -0.37% | 2024-12-31 |
| Avoro Capital Advisors Llc | $170,667.00 | 8.11% | 11.11M | +2M | +25% | 2024-12-31 |
| State Street Corp | $92,409.00 | 4.39% | 6.02M | -338,104 | -5.32% | 2024-12-31 |
| Slate Path Capital Lp | $80,364.00 | 3.82% | 5.23M | +347,000 | +7.1% | 2024-12-31 |
| Fmr Llc | $78,353.00 | 3.72% | 5.1M | -966,486 | -15.93% | 2024-12-31 |
| Geode Capital Management, Llc | $45,388.00 | 2.16% | 2.95M | -9,172 | -0.31% | 2024-12-31 |
| Siren, L.L.C. | $44,570.00 | 2.12% | 2.9M | +442,903 | +18.01% | 2024-12-31 |
| T. Rowe Price Investment Management, Inc. | $38,512.00 | 1.83% | 2.51M | -1M | -29.86% | 2024-12-31 |
| Norges Bank | $31,555.00 | 1.5% | 2.05M | +469,044 | +29.59% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.